Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Calgenex’ Dermalleve

This article was originally published in The Tan Sheet

Executive Summary

Tampa, Fla.-based Calgenex announces the launch of Dermalleve, an over-the-counter topical treatment for psoriasis, eczema and seborrheic dermatitis that combines 1% hydrocortisone with natural ingredients to moisturize and nourish skin, the firm states Sept. 27. The product contains natural ingredients such as alpha-hydroxy acids, skin-nourishing nutrients and skin conditioners such as aloe vera, shea butter, vitamin E, jojoba oil and silicone. The product "helps to gently remove dead skin cells while skin-nourishing nutrients, conditioners and moisturizers support healthy skin," Calgenex says. Demalleve also applies easily and evenly because it has the consistency of a lubricant unlike other anti-itch creams which can be too thick, the company asserts. The product is available on Calgenex's website for $19.95 and the firm is supporting the launch with radio ads and TV infomercials...

You may also be interested in...

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.

What’s Next? Five Things To Look Out For In March

In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts